LOS
ANGELES, Feb. 26, 2024 /PRNewswire/ -- Aadi
Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company
focused on developing and commercializing precision therapies for
patients with mTOR pathway alterations, announced today its
presentation at the TD Cowen 44th Annual Healthcare
Conference, taking place March 4-6,
2024, in Boston.
Dave Lennon, Ph.D., President and CEO, will present a
company overview on Monday, March 4, 2024, from 2:10 PM – 2:40 PM
ET.
The presentation will be webcast live on the IR pages of
the Aadi Bioscience website and will be available
for replay for approximately 30 days following each investor
event.
About Aadi Bioscience, Inc.
Aadi is a commercial-stage biopharmaceutical company focused on
precision therapies for cancers to bring transformational therapies
to cancer patients with alterations in the mTOR pathway, a key
regulator of cell growth and cancer progression. Aadi received FDA
approval and has commercialized FYARRO® for the treatment of adult
patients with locally advanced unresectable or metastatic malignant
perivascular epithelioid cell tumor (PEComa).
Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic
registration-intended trial in mTOR inhibitor-naïve malignant solid
tumors
harboring TSC1 or TSC2 inactivating
alterations. More information on the Company's development pipeline
is available on the Aadi website at www.aadibio.com and
connect with us on Twitter and LinkedIn.
Contact:
IR@aadibio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-present-at-the-td-cowen-44th-annual-healthcare-conference-302071520.html
SOURCE Aadi Bioscience